Background
Escherichia coli
is one of the most common strains of extended-spectrum β-lactam (ESBL)-producing bacteria, and the prevention and treatment of ESBL-producing
E. coli
infections is an ongoing challenge. The clinical characteristics and outcomes of ESBL-producing
E. coli
bacteremia in non-transplant patients remain to be elucidated.
Methods
This retrospective study included 491 non-transplant patients with
E. coli
bloodstream infections (BSIs) from January 2013 to December 2016 and was conducted to investigate the risk factors, clinical features, and outcomes of these infections.
Results
Of the 491
E. coli
BSI patients, 57.6% suffered from infections with ESBL-producing strains. A multivariate analysis showed that urinary tract infection, prior use of cephalosporin, and treatment with β-lactam-β-lactamase inhibitor (BLBLI) combination antibiotics were independent risk factors for the development of ESBL-producing
E. coli
BSIs. The overall mortality rate in
E. coli
BSI patients was 14.46%, and there was no significant difference in the 28 day mortality rate between ESBL-producing
E. coli
and non-ESBL-producing
E. coli
BSI patients (14.8% vs. 14.0%, respectively;
P
= 0.953). Similarly, there was no difference between the community-acquired infection group and the nosocomial infection group. Hepatobiliary disease, carbapenem exposure, high APACHE II score, and hypoproteinemia were independent risk factors for death in
E. coli
BSI patients. Multivariate analysis showed that hypoproteinemia and severe disease were independent risk factors for death from
ESBL
-producing
E. coli
BSIs. Furthermore, there was no significant difference in the 28 day mortality between patients with
ESBL
-producing
E. coli
BSIs treated with carbapenem monotherapy versus those treated with BLBLI combination antibiotics (12.8% vs. 17.9%, respectively;
P
= 0.384).
Conclusions
Prior use of cephalosporin or BLBLI combination antibiotics increased the risk ratio for
ESBL
-producing
E. coli
infection. Hypoproteinemia and severe disease are independent risk factors for death in patients with
E. coli
BSIs. There was no significant difference in the 28 day prognosis of patients with ESBL-producing
E. coli
and those with non-ESBL-producing
E. coli
BSIs. These data do not support the conclusion that carbapenems might be more effective than BLBLI antibiotics for treatment of patients with BSIs cau...